Current status and progress of drug therapy for portal hypertension in China

doi:10.3877/cma.j.issn.2095-2015.2019.06.003

Abstract

Abstract:

Portal hypertension is a group of syndrome characterized by abnormal changes of portal blood flow system. The main complication is esophageal and gastric variceal bleeding. The treatment of portal hypertension is mainly for the treatment of bleeding. The treatment strategies include primary prevention, control of acute bleeding and secondary prevention. There are many treatment methods, and reasonable selection is very important. Among them, drug treatment plays an important role in the treatment of portal hypertension. The aim of this article is to introduce the current status and progress of drug treatment in China.

Key words: Cirrhosis, Portal hypertension, Esophageal-gastro varices, Therapy

Yiguo Wang, Xinli Ma. Current status and progress of drug therapy for portal hypertension in China[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2019, 09(06): 248-251.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2019.06.003

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2019/V09/I06/248

References 32

1	中国门静脉高压诊断与监测研究组(CHESS)，中华医学会消化病学分会微创介入协作组，中国医师协会介入医师分会急诊介入专业委员会．中国肝静脉压力梯度临床应用专家共识(2018版)[J]．中华消化杂志，2018，38(11):728.
2	彭颖，祁兴顺，郭晓钟.2015年BavenoⅥ共识：门静脉高压的风险分层及个体化管理[J]．临床肝胆病杂志，2015(8):1202-1207.
3	徐小元，丁惠国，李文刚，等．肝硬化诊治指南[J]．临床肝胆病杂志，2019，35(11):2408-2407.
4	张静，陈明锴．门脉高压症的诊断与治疗进展[J]．胃肠病学和肝病学杂志，2018(3):341-345.
5	王建荣，陆文霞，夏玉敬，等．门脉高压药物治疗进展[J]．世界临床药物，2016，289(1):70-75.
6	中国医师协会急诊医师分会．急性上消化道出血急诊诊治流程专家共识[J]．中国急救医学，2015(35):873.
7	D′Amico G, Pagliaro L, Bosch J．Pharmacological Treatment of Portal Hypertension：An Evidence-Based Approach[J]．Semin Liver Dise，1999，19(4):475-505.
8	Osterman M．A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding[J]．Yearbook of Gastroenterology，2007，2007:167-168.
9	Bosch J, Juan Carlos García-Pagán.Complications of cirrhosis.I.Portal Hypertension[J]．J Hepatol，2000，32(1 Suppl):141-156.
10	中华医学会肝病学分会，中华医学会消化病学分会，中华医学会消化内镜学分会．肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]．中华内科杂志，2016，55(1):57-72.
11	周光文，杨连粤．肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2015)[J]．中国实用外科杂志，2015(10):1086-1090.
12	Sharma M, Singh S, Desai V，et al.Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding：A Systematic Review and Network Meta-analysis[J]．Hepatology，2019，69(4):1657-1675.
13	Garcia-Tsao G, Abraldes J G, Berzigotti A，et al.Portal Hypertensive Bleeding in Cirrhosis：Risk Stratification，Diagnosis and Management-2016 Practice Guidance by the American Association for the Study of Liver Diseases[J]．Hepatology，2016，65(1):310-335.
14	Garcia-Tsao G, Bosch J．Management of varices and variceal hemorrhage in cirrhosis[J]．N Engl J Med，2010，362(9):823-832.
15	Reiberger T, Ulbrich G, Ferlitsch A，et al.Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J]．Gut，2013，62(11):1634-1641.
16	Gupta V, Rawat R, Shalimar，et al.Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed：RCT[J]．Hepatol Int，2017，11(2):181-187.
17	Abid S, Ali S, Baig M A，et al.Is it time to replace propranolol with carvedilol for portal hypertension？[J]．World J Gastrointest Endosc，2015，7(5):532-539.
18	Sánchez del Monte J, Ramos Gómez MV, Velazquez Ochoa E．Comparative study of propranolol versus propranolol plus isosorbide 5-mononitrate in portal hypertension in cirrhotics.Evaluating splanchnic hemodynamics with color Doppler ultrasound[J]．Rev Gastroenterol Mex，2005，70(3):261-268.
19	Kamath, Patrick S．Esophageal variceal bleeding：Primary prophylaxis[J]．Clin Gastroenterol Hepatol，2005，3(1):90-93.
20	侯辉，程云生．门脉高压症的综合治疗进展[J]．医学综述，2010，16(13):2027-2029.
21	Tandon P, Abraldes JG, Berzigotti A，et al.Renin-angiotensinaldosterone inhibitors in the reduction of portal pressure：a systematic review and meta-analysis[J]．J Hepatol，2010，53(2):273-282.
22	Park D H, Baik S K, Choi Y H，et al.Inhibitory effect of angiotensin blockade on hepatic fibrosis in common bile duct-ligated rats[J]．Korean J Hepatol，2007，13(1):61-69.
23	Kim JH, Kim JM, Cho YZ，et al.Effects of candesartan and pro-pranolol combination therapy versus propranolol monotherapy in reducing portal hypertension.Clin Mol Hepatol，2014，20(4):376-383.
24	Zafra C, Abraldes JG, Turnes J，et al.Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis[J]．Gastroenterology，2004，126(3):749-755.
25	Harnois DM.Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension：A Randomized Controlled Trial[J]．Yearbook of Medicine，2010，2010:468-469.
26	Abraldes JG, Villanueva C, Aracil C，et al.Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis.Gastroenterology，2016，150(5):1160-1170.e3.
27	Aina Rodríguez-Vilarrupla, Bàrbara Lavina, Héctor García-Calderó，et al.PPARαactivation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats[J]．J Hepatol，2012，56(5):0-1039.
28	Mejias M, Ester Garcia-Pras, Tiani C，et al.Beneficial effects of sorafenib on splanchnic，intrahepatic，and portocollateral circulations in portal hypertensive and cirrhotic rats[J]．Hepatology，2009，49(4):1245-1256.
29	朱云，李爱民，罗荣城．索拉非尼对门静脉高压症的治疗作用及其机制[J]．南方医科大学学报，2014(1):133-136.
30	D′Amico M, Mejías M, García-Pras E，et al.Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats[J]．AJP Gastroint Liver Physiol，2012，302(10):G1191-1198.
31	Dong T, Aronsohn A, Reddy K G，et al.Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis[J]．Dig Dis Sci，2016，61(12):1-6.
32	吕新月，李磊．利福昔明在肝硬化相关并发症中的应用[J]．临床肝胆病杂志，2018，34(7):190-193.

[1]	Wei Zhang. Dentoalveolar surgery: The pioneer of comfortable treatment [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(06): 386-388.
[2]	Yanhui Zhang, Jiao Zhang, Zhixian Zhu. Effect of indwelling anal tube on anastomotic leakage after laparoscopic total mesangectomy after neoadjuvant chemoradiotherapy in patients with middle and low rectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 25-28.
[3]	Jianmei Li, Jingjuan Deng, Qian Yang. Safety and follow-up evaluation of the combined treatment of hepatocellular carcinoma with hepatic cirrhosis and portal hypertension [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 41-44.
[4]	Fangyuan Wu, Xia Sun, Changfeng Lin, Zhensheng Zhang. Risk factors of HBV-associated cirrhosis complicated with acute upper gastrointestinal bleeding [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 45-47.
[5]	Xian Mo, Chuang Yang. Meta-analysis of risk factors for portal vein thrombosis in patients with cirrhosis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 678-683.
[6]	Zhibo Gu, lin Hao, Ming Lu, Jiangang Chen. Photodynamic nanocarriers combined with siP3H4 for precise targeting therapy in the treatment of bladder cancer: a pilot study [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(06): 633-641.
[7]	Xiaoyong Wei. Discussion on the focus issues of conversion therapy for primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 602-607.
[8]	Chenrui Wu, Rui Liao, Qiang He. Hepatic arterial infusion chemotherapy combined immunotargeted therapy for multiple metastatic hepatocellular carcinoma in a multi-disciplinary treatment model: a case report [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 713-716.
[9]	Guangjun Zhong, Chunhua Liu, Wansen Zhu, Xiaolei Xu, Zhaojun Wang. Application of conventional MRI combined with different scanning sequences in preoperative staging diagnosis, chemotherapy efficacy and prognosis evaluation of gastric cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 378-382.
[10]	Qiujie Shan, Lizhu Sun, Yiquan Xu, Zhixia Wang, Yan Xu, Hao Ma, Tiantian Liu. Construction and application of radiation-induced lung injury risk model for middle-aged and elderly patients with esophageal cancer during intensity modulated radiotherapy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 388-393.
[11]	Baoru Hu, Naijian Shang, Di Gao. DCE-MRI and DWI findings of advanced hepatocellular carcinoma and their correlation with prognosis after immunotherapy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 399-403.
[12]	Wei Qin, Dan Wang, Yu Sun, Yuling Huo, Suping Zhu, Yanli Zheng, Rui Xue. Predictive value of serum laminin and typeⅣcollagen on liver cirrhosis with ophageal and gastric varices bleeding [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 447-451.
[13]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[14]	Fanbiao Kong, Jianrong Yang. Progress in understanding of relationship between underlying liver diseases and liver metastasis of colorectal cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 818-822.
[15]	Meisha Fu, Yuhua Zhou, Hui Li, Chunyan Xue. Effect of lymphocyte immunotherapy on T lymphocyte subset distribution and PD1/PD-L1 expression in patients with recurrent miscarriage [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 726-730.

Please choose a citation manager

Content to export